Comparative Effectiveness of Calcium-Channel Blockers, Angiotensin-Converting Enzyme/Angiotensin Receptor Blockers and Diuretics on Cardiovascular Events Likelihood in Hypertensive African-American and Non-Hispanic Caucasians: A Retrospective Study...

Overview

Journal Clin Cardiol

Date 2025 Jan 21

PMID 39835349

Authors

Anil Harrison

Sushil Rayamajhi

Farhad Shaker

Schwartz Thais

Melissa Moreno

Kaveh Hosseini

Affiliations

Soon will be listed here.

Abstract

Background: Hypertension, a leading global risk factor for mortality and disability, disproportionately affects racial and ethnic minorities. Our study investigates the association between the type of prior antihypertensive medication use and the likelihood of cardiovascular events (CVE) and assesses whether the patient's race influences this relationship.

Methods: A retrospective study of 14 836 hypertension cases aged ≥ 40 years was conducted using data from HCA Healthcare between 2017 and 2023. Logistic regression was employed to predict the likelihood of CVE and mortality at admission, adjusting for baseline comorbidities, with Race added as an effect modifier. Interaction analysis was performed among races based on antihypertensive medication types.

Results: African American patients on ACE inhibitors (ACE) or angiotensin receptor blockers (ARBs) were 1.7 times more likely to have cardiovascular events (CVE) compared to those on calcium channel blockers (CCBs) and 0.66 times as likely compared to diuretics. CCB users had a lower CVE risk than diuretic users. Among White patients, ACE/ARB users had a 1.18 times higher CVE risk than CCB users and 0.45 times lower compared to diuretics, while CCBs offered a 0.38 times lower risk than diuretics. Only ACE/ARB use showed significantly higher CVE odds for African Americans compared to White patients, with similar risks across racial groups for CCBs and diuretics.

Conclusion: Prior antihypertensive type significantly influenced CVE risk, with race as an effect modifier. CCB users had lower CVE odds than ACE/ARBs or diuretics, and ACE/ARBs showed reduced CVE likelihood compared to diuretics in both racial groups.

References

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

Nguyen T, Kaufman J, Whitsel E, Cooper R . Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis. Am J Hypertens. 2009; 22(8):911-7. PMC: 6414055. DOI: 10.1038/ajh.2009.100. View

Forouzanfar M, Alexander L, Anderson H, Bachman V, Biryukov S, Brauer M . Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(10010):2287-323. PMC: 4685753. DOI: 10.1016/S0140-6736(15)00128-2. View

Ogedegbe G, Shah N, Phillips C, Goldfeld K, Roy J, Guo Y . Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites. J Am Coll Cardiol. 2015; 66(11):1224-1233. PMC: 4567693. DOI: 10.1016/j.jacc.2015.07.021. View

Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View

Zanchetti A, Julius S, Kjeldsen S, McInnes G, Hua T, Weber M . Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens. 2006; 24(11):2163-8. DOI: 10.1097/01.hjh.0000249692.96488.46. View

Sehgal A . Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004; 43(3):566-72. DOI: 10.1161/01.HYP.0000118019.28487.9c. View

10.

Sinnott S, Douglas I, Smeeth L, Williamson E, Tomlinson L . First line drug treatment for hypertension and reductions in blood pressure according to age and ethnicity: cohort study in UK primary care. BMJ. 2020; 371:m4080. PMC: 7670766. DOI: 10.1136/bmj.m4080. View

11.

Khera R, Lu Y, Lu J, Saxena A, Nasir K, Jiang L . Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. BMJ. 2018; 362:k2357. PMC: 6039831. DOI: 10.1136/bmj.k2357. View

12.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33):3021-3104. DOI: 10.1093/eurheartj/ehy339. View

13.

Brewster L, Seedat Y . Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med. 2013; 11:141. PMC: 3681568. DOI: 10.1186/1741-7015-11-141. View

14.

Flack J, Nasser S, Levy P . Therapy of hypertension in African Americans. Am J Cardiovasc Drugs. 2011; 11(2):83-92. DOI: 10.2165/11586930-000000000-00000. View

15.

Bosworth H, Dudley T, Olsen M, Voils C, Powers B, Goldstein M . Racial differences in blood pressure control: potential explanatory factors. Am J Med. 2006; 119(1):70.e9-15. DOI: 10.1016/j.amjmed.2005.08.019. View

16.

Javed Z, Maqsood M, Yahya T, Amin Z, Acquah I, Valero-Elizondo J . Race, Racism, and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic Disparities in Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2022; 15(1):e007917. DOI: 10.1161/CIRCOUTCOMES.121.007917. View

17.

Prisant L, Thomas K, Lewis E, Huang Z, Francis G, Weaver W . Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. J Am Coll Cardiol. 2008; 51(19):1865-71. DOI: 10.1016/j.jacc.2007.12.050. View

18.

Chekka L, Chapman A, Gums J, Cooper-DeHoff R, Johnson J . Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. Am J Med. 2021; 134(7):918-925.e2. PMC: 8243781. DOI: 10.1016/j.amjmed.2020.12.015. View

19.

Law M, Morris J, Wald N . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338:b1665. PMC: 2684577. DOI: 10.1136/bmj.b1665. View

20.

Tamargo J, Kaski J, Kimura T, Barton J, Yamamoto K, Komiyama M . Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events. Eur Heart J Cardiovasc Pharmacother. 2022; 8(7):738-751. PMC: 9520447. DOI: 10.1093/ehjcvp/pvac040. View